Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling
Kwan-Young Jung,Ramin Samadani,Jay Chauhan,Kerrick Nevels,Jeremy L. Yap,Jun Zhang,Shilpa Worlikar,Maryanna E. Lanning,Lijia Chen,Mary Ensey,Sagar Shukla,Rosene Salmo,Geoffrey Heinzl,Caryn Gordon,Troy Dukes
Abstract
We herein report on the pharmacophore determination of the ERK docking domain inhibitor (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione, which has led to the discovery of compounds with greater selectivities for inhibiting the proliferation of melanoma cells containing active ERK signaling.
